Estimation of time to reach RRMS EDSS health states >= 7.0 Or SPMS for delayed-release dimethyl fumarate
Multiple sclerosis (MS) disease progression is measured by the Expanded Disability Status Scale (EDSS). UK MS clinical guidelines1recommend that patients discontinue treatment with disease modifying therapies (DMTs) on reaching EDSS ?7.0, or experiencing non-relapsing secondary progressive MS (SPMS). This study derived the time for patients to reach EDSS ?7.0 or SPMS from EDSS 4.0 or 5.0, for patients treated with delayed-release dimethyl fumarate 240mg (DMF; also known as gastro-resistant DMF), or no DMT treatment.
Walker, A., Berling, M., Malmenas, M., Brodtkorb, T-H., & Alvarez-Reyes, M. (2015). Estimation of time to reach RRMS EDSS health states >= 7.0 Or SPMS for delayed-release dimethyl fumarate. Value in Health, 18(3), A279. DOI: 10.1016/j.jval.2015.03.1632